|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
A SEER-Medicare Based Quality Score for Patients with Both Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma
|
Daniel Joyce, MD
Daniel Joyce joins Sam Chang to discuss oncologic outcomes, costs, and quality metrics for patients with both synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
|
|
|
|
|
|
|
|
|
|
|
| Neoadjuvant Nivolumab and Ipilimumab for Upper Tract Urothelial Cancer |
Min Yuen Teo, MD
Min Yuen Teo joins Sam Chang in a discussion on an ongoing Phase II clinical trial on neoadjuvant immune checkpoint inhibition, with both a combination of nivolumab and ipilimumab in patients with high grade invasive upper tract urothelial cancer who are cisplatin-ineligible. |
|
|
|
|
|
|
|
|
|
|
|
The Impact of a Neoadjuvant Chemotherapy Treatment Prior to Radical Nephroureterectomy for Patients with High-Grade Upper Tract Urothelial Carcinoma
|
Jonathan Coleman, MD, and Wesley Yip, MD
Wesley Yip and Jonathan Coleman join Sam Chang in a conversation discussing the impact of neoadjuvant chemotherapy prior to radical nephroureterectomy and its possible benefit on patients with high-grade upper tract urothelial carcinoma. |
|
|
|
|
|
|
|
|
|
|
| A SEER-Medicare Based Quality Score for Patients with Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma and Its Association with Cost of Care and Survival |
| Daniel D. Joyce, MD |
| Given the scarcity of UTUC, and particularly mUTUC, there is a limited literature base of population-based studies evaluating outcomes exclusively for metastatic upper tract urothelial carcinoma (mUTUC). The available literature is further limited by only capturing patients with de novo (synchronous) metastases as opposed to those who progress to metastatic disease (metachronous). |
|
|
|
|
|
| Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer |
| Min Yuen Teo, MD, MRCP |
| Upper tract urothelial carcinoma is associated with a poor prognosis despite radical nephroureterectomy. Similar to urothelial carcinoma of the bladder, outcomes are improved with perioperative platinum-based chemotherapy. Also similar to other urothelial cancers not all patients are eligible for platinum-based chemotherapy, often due to renal insufficiency, performance status, or antecedent neuropathy. |
|
|
|
|
|
|
|
|
|
|
| Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Patients with Clinically Node-Positive Upper Tract Urothelial Cancer (UTUC) Who Underwent Radical Nephroureterectomy
|
| Karan Jatwani, MD
|
| In this retrospective analysis of outcomes among patients with clinically node positive UTUC who underwent a radical nephroureterectomy, neoadjuvant chemotherapy use, compared to adjuvant chemotherapy, was associated with a significantly improved overall survival hazard.
|
|
|
|
|
|
| Oncologic Outcomes in Patients with Residual Invasive Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy |
| Sean A. Fletcher, MD |
| Patients with UTUC who have residual muscle invasive disease following NAC have poorer outcomes than stage-matched chemotherapy naïve counterparts. This may reflect effects of occult micrometastatic disease or chemoresistant primary tumors in non-responders. |
|
|
|
|
|
| Radical Nephroureterectomy Followed by Adjuvant Chemotherapy Versus Observation in Early-Stage Upper Urinary Tract Cancers with Variant Histology |
| Karan Jatwani, MD |
| UTUC occurs less commonly and is associated with a worse stage-for-stage prognosis compared to urothelial carcinoma of the bladder, with variant histology being an independent predictor of worse outcomes. The POUT trial disproportionately included patients with urothelial predominant tumors. As such, the objective of this study was to evaluate outcomes of patients with UTUC variant histology who underwent adjuvant chemotherapy versus observation following an RNU. |
|
|
|
|
|
|
